A clinical trial to learn how an investigational drug (norucholic acid) is absorbed, distributed, broken down, and removed from the body when given to people with kidney problems

2023-505862-27-00 Protocol NUT-018/BIO Human pharmacology (Phase I) - Other Ended

Start 10 Oct 2023 · End 17 Apr 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol NUT-018/BIO

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 48
Countries 1
Sites 1

Nonalcoholic fatty liver disease (NAFLD)

Key facts

Sponsor
Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
10 Oct 2023 → 17 Apr 2025
Decision date (initial)
2023-10-06
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Nonalcoholic fatty liver disease (NAFLD)

VersionLevelCodeTermSystem organ class
22.0 LLT 10029530 Non-alcoholic fatty liver 10019805
20.1 LLT 10036732 Primary sclerosing cholangitis 10019805
22.0 PT 10053219 Non-alcoholic steatohepatitis 100000004871

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Dr. Falk Pharma GmbH

Sponsor organisation
Dr. Falk Pharma GmbH
Address
Leinenweberstrasse 5, Hochdorf Hochdorf
City
Freiburg Im Breisgau
Postcode
79108
Country
Germany

Scientific contact point

Organisation
Dr. Falk Pharma GmbH
Contact name
CTIS – Scientific Request

Public contact point

Organisation
Dr. Falk Pharma GmbH
Contact name
Clinical Research and Development

Dr. Falk Pharma GmbH

Sponsor organisation
Dr. Falk Pharma GmbH
Address
Leinenweberstrasse 5, Hochdorf Hochdorf
City
Freiburg Im Breisgau
Postcode
79108
Country
Germany

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Hungary Ended 48 1
Rest of world 0

Investigational sites

Hungary

1 site · Ended
CRU Hungary Kft.
Early Phase Unit, Semmelweis Ter 1, 2143, Kistarcsa

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Hungary 2023-10-10 2025-04-17 2023-10-10 2025-03-13

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-07-05 Hungary Acceptable
2023-08-28
2023-10-06
2 SUBSTANTIAL MODIFICATION SM-1 2024-02-12 Hungary Acceptable 2024-03-18
3 SUBSTANTIAL MODIFICATION SM-2 2024-04-16 Hungary Acceptable
2024-05-07
2024-05-13